146 related articles for article (PubMed ID: 26909985)
1. Genetic variability of CYP3A4 in a heterogeneous Brazilian population from Maranhão.
Monteiro SC; de Sousa IH; Belfort IK; Nunes JD; Penha BA; dos Santos M; Drumond Louro I; da Silva ID
Genet Mol Res; 2016 Feb; 15(1):. PubMed ID: 26909985
[TBL] [Abstract][Full Text] [Related]
2. Characterization of CYP1A2, CYP2C19, CYP3A4 and CYP3A5 polymorphisms in South Brazilians.
Kohlrausch FB; Carracedo Á; Hutz MH
Mol Biol Rep; 2014 Mar; 41(3):1453-60. PubMed ID: 24443221
[TBL] [Abstract][Full Text] [Related]
3. Genetic contribution to variable human CYP3A-mediated metabolism.
Lamba JK; Lin YS; Schuetz EG; Thummel KE
Adv Drug Deliv Rev; 2002 Nov; 54(10):1271-94. PubMed ID: 12406645
[TBL] [Abstract][Full Text] [Related]
4. Distribution of alleles, genotypes and haplotypes of the CYP2B6 (rs3745274; rs2279343) and CYP3A4 (rs2740574) genes in the Malian population: Implication for pharmacogenetics.
Kassogue Y; Diakite B; Kassogue O; Konate I; Tamboura K; Diarra Z; Maiga M; Dehbi H; Nadifi S; Traore CB; Kamate B; Dao S; Doumbia S; Dolo G
Medicine (Baltimore); 2021 Jul; 100(29):e26614. PubMed ID: 34398016
[TBL] [Abstract][Full Text] [Related]
5. Naturalistic pharmacogenetic study of treatment resistance to typical neuroleptics in European-Brazilian schizophrenics.
Kohlrausch FB; Gama CS; Lobato MI; Belmonte-de-Abreu P; Callegari-Jacques SM; Gesteira A; Barros F; Carracedo A; Hutz MH
Pharmacogenet Genomics; 2008 Jul; 18(7):599-609. PubMed ID: 18551040
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetics in American Indian populations: analysis of CYP2D6, CYP3A4, CYP3A5, and CYP2C9 in the Confederated Salish and Kootenai Tribes.
Fohner A; Muzquiz LI; Austin MA; Gaedigk A; Gordon A; Thornton T; Rieder MJ; Pershouse MA; Putnam EA; Howlett K; Beatty P; Thummel KE; Woodahl EL
Pharmacogenet Genomics; 2013 Aug; 23(8):403-14. PubMed ID: 23778323
[TBL] [Abstract][Full Text] [Related]
7. Genetic analysis of drug metabolizing phase-I enzymes CYP3A4 in Tibetan populations.
Liu L; Chang Y; Du S; Shi X; Yang H; Kang L; Jin T; Yuan D; He Y
J Genet; 2017 Jun; 96(2):219-225. PubMed ID: 28674221
[TBL] [Abstract][Full Text] [Related]
8. Distribution of allelic and genotypic frequencies of IL1A, IL4, NFKB1 and PAR1 variants in Native American, African, European and Brazilian populations.
Amador MA; Cavalcante GC; Santos NP; Gusmão L; Guerreiro JF; Ribeiro-dos-Santos Â; Santos S
BMC Res Notes; 2016 Feb; 9():101. PubMed ID: 26879815
[TBL] [Abstract][Full Text] [Related]
9. Unique CYP3A4 genetic variant in Brazilian tuberculosis patients with/without HIV.
Jeovanio-Silva AL; Monteiro TP; El-Jaick KB; do Brasil PE; Rolla VC; de Castro L
Mol Med Rep; 2012 Jan; 5(1):153-61. PubMed ID: 21964586
[TBL] [Abstract][Full Text] [Related]
10. Defining screening panel of functional variants of CYP1A1, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 genes in Serbian population.
Skadrić I; Stojković O
Int J Legal Med; 2020 Mar; 134(2):433-439. PubMed ID: 31858263
[TBL] [Abstract][Full Text] [Related]
11. High predictive value of CYP2B6 SNPs for steady-state plasma efavirenz levels in South African HIV/AIDS patients.
Swart M; Skelton M; Ren Y; Smith P; Takuva S; Dandara C
Pharmacogenet Genomics; 2013 Aug; 23(8):415-27. PubMed ID: 23778320
[TBL] [Abstract][Full Text] [Related]
12. Characterization of CYP3A pharmacogenetic variation in American Indian and Alaska Native communities, targeting CYP3A4*1G allele function.
Fohner AE; Dalton R; Skagen K; Jackson K; Claw KG; Hopkins SE; Robinson R; Khan BA; Prasad B; Schuetz EG; Nickerson DA; Thornton TA; Dillard DA; Boyer BB; Thummel KE; Woodahl EL
Clin Transl Sci; 2021 Jul; 14(4):1292-1302. PubMed ID: 33503331
[TBL] [Abstract][Full Text] [Related]
13. Analysis of single-nucleotide polymorphisms (SNPs) in human CYP3A4 and CYP3A5 genes: potential implications for the metabolism of HIV drugs.
Berno G; Zaccarelli M; Gori C; Tempestilli M; Antinori A; Perno CF; Pucillo LP; D'Arrigo R
BMC Med Genet; 2014 Jul; 15():76. PubMed ID: 24986243
[TBL] [Abstract][Full Text] [Related]
14. Analysis of pharmacogenetic traits in two distinct South African populations.
Ikediobi O; Aouizerat B; Xiao Y; Gandhi M; Gebhardt S; Warnich L
Hum Genomics; 2011 May; 5(4):265-82. PubMed ID: 21712189
[TBL] [Abstract][Full Text] [Related]
15. CYP3A genotypes in Bangladeshi tuberculosis patients.
Maruf AA; Ahmed MU; Azad MA; Ahmed M; Hasnat A
Bangladesh Med Res Counc Bull; 2012 Apr; 38(1):1-5. PubMed ID: 22545342
[TBL] [Abstract][Full Text] [Related]
16. [CYP2D6, CYP3A5, and CYP3A4 gene polymorphism in Russian, Tatar, and Bashkir populations].
Mustafina OE; Tuktarova IA; Karimov DD; Somova Rs; Nasibullin TR
Genetika; 2015 Jan; 51(1):109-19. PubMed ID: 25857198
[TBL] [Abstract][Full Text] [Related]
17. Group-based pharmacogenetic prediction: is it feasible and do current NHS England ethnic classifications provide appropriate data?
Ingram CJE; Ekong R; Ansari-Pour N; Bradman N; Swallow DM
Pharmacogenomics J; 2021 Feb; 21(1):47-59. PubMed ID: 32683419
[TBL] [Abstract][Full Text] [Related]
18. D1S80 locus variability in three Brazilian ethnic groups.
Heidrich EM; Hutz MH; Salzano FM; Coimbra CE; Santos RV
Hum Biol; 1995 Apr; 67(2):311-9. PubMed ID: 7729831
[TBL] [Abstract][Full Text] [Related]
19. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.
Staatz CE; Goodman LK; Tett SE
Clin Pharmacokinet; 2010 Mar; 49(3):141-75. PubMed ID: 20170205
[TBL] [Abstract][Full Text] [Related]
20. Effect of Multidrug-Resistant 1 (MDR1) and CYP3A4*1B Polymorphisms on Cyclosporine-Based Immunosuppressive Therapy in Renal Transplant Patients.
Kotowski MJ; Bogacz A; Bartkowiak-Wieczorek J; Tejchman K; Dziewanowski K; Ostrowski M; Czerny B; Grześkowiak E; Machaliński B; Sieńko J
Ann Transplant; 2019 Feb; 24():108-114. PubMed ID: 30799432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
